학술논문
LBA66 IMmotion010: Efficacy and safety from the phase III study of atezolizumab (atezo) vs placebo (pbo) as adjuvant therapy in patients with renal cell carcinoma (RCC) at increased risk of recurrence after resection
Document Type
Abstract
Author
Source
In Annals of Oncology September 2022 33 Supplement 7:S1431-S1432
Subject
Language
ISSN
0923-7534